Market Performance - U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Monday [1] - The Dow increased by 0.18% to 48,222.17, the NASDAQ rose by 0.56% to 23,439.24, and the S&P 500 climbed 0.45% to 6,864.96 [1] Sector Performance - Energy shares rose by 1.3% on Monday [1] - Utilities stocks fell by 0.5% during the same trading session [1] Commodity Prices - Oil prices increased by 2.2% to $57.75 [4] - Gold prices rose by 1.7% to $4,463.30 [4] - Silver prices went up by 2.5% to $69.150, while copper prices fell by 0.1% to $5.5085 [4] European Market Trends - European shares were lower, with the eurozone's STOXX 600 declining by 0.3% [5] - Spain's IBEX 35 Index fell by 0.2%, London's FTSE 100 decreased by 0.5%, Germany's DAX 40 dropped by 0.3%, and France's CAC 40 fell by 0.5% [5] Asian Market Trends - Asian markets closed higher, with Japan's Nikkei 225 gaining 1.81%, Hong Kong's Hang Seng rising by 0.43%, China's Shanghai Composite increasing by 0.69%, and India's BSE Sensex up by 0.75% [6] Notable Stock Movements - Haoxin Holdings Limited (NASDAQ:HXHX) shares surged by 118% to $0.7513 [8] - Sidus Space, Inc. (NASDAQ:SIDU) shares increased by 78% to $2.0650 after receiving a contract from the Missile Defense Agency [8] - Jyong Biotech Ltd. (NASDAQ:MENS) shares rose by 36% to $4.32 [8] - Luminar Technologies, Inc. (NASDAQ:LAZR) shares dropped by 60% to $0.2396 after announcing voluntary Chapter 11 proceedings [8] - EUDA Health Holdings Limited (NASDAQ:EUDA) shares fell by 25% to $2.09 following a strategic technology integration announcement [8] - Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) shares decreased by 20% to $1.74 due to a self tender offer announcement [8]

Core Points - Cytokinetics held a conference call to discuss the FDA approval of MYQORZO [1] Group 1 - The conference call was led by Diane Weiser, the Senior Vice President of Corporate Affairs at Cytokinetics [1]

Core Insights - The Trump administration has signed drug-pricing agreements with several large-cap drugmakers to lower drug prices in the U.S. [1] - The agreements require drugmakers to reduce prescription drug prices to match those in comparable developed countries, supporting the Most Favored Nation (MFN) pricing proposal [2] - Drugmakers will receive a three-year exemption from import tariffs on pharmaceutical ingredients in exchange for expanding domestic manufacturing operations [3] - Some companies will donate active pharmaceutical ingredients (APIs) to a government stockpile to ensure supply chain resilience during emergencies [4] - The Trump administration has now reached deals with 14 out of 17 targeted drug manufacturers, with three companies still in discussions [5] Industry Impact - The agreements address major concerns regarding drug pricing and tariffs, improving investor outlook for the pharmaceutical sector [6] - The deals are seen as a turning point that could alleviate regulatory and pricing pressures on the industry [7] - The latest agreements involve nine major drugmakers, joining others like Pfizer and AstraZeneca who signed similar deals earlier [8]

Key Takeaways EyePoint's late-stage retinal programs and upcoming data readouts position it for momentum beyond 2025.ANI Pharmaceuticals' rare disease franchise is scaling fast, led by surging Cortrophin Gel sales.Tango Therapeutics is advancing precision oncology with promising PRMT5 inhibitorsThe biotech sector has put up a strong recovery in 2025. The Nasdaq Biotechnology Index has risen 33.1% so far this year. The index bottomed out in April 2025 on potential imposition of steep tariffs, which weighed h ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy in 2026. On December 15, Bank of America analyst Jason Gerberry lowered the firm’s price target on Eli Lilly to $1,268 from $1,286 with a Buy rating on the shares. BofA remains bullish on Eli Lilly’s stock due to the company’s successful obesity product launches and the steady expansion of its pipeline into new therapeutic areas. 2027 projected earnings are expected to better capture the company’s long-term growth potential. In othe ...

Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy according to hedge funds. On December 15, Goldman Sachs lifted its price target on Eli Lilly and Company (NYSE:LLY) to $1,145 from $951 while reiterating a Buy rating on the stock. Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment Pixabay/Public Domain On December 12, Eli Lilly and Company provided updated data for its oral estrogen receptor antagonist Inluriyo (imlunestrant) currently in Pha ...

All right, we're gonna start with this MAG7 chart, right. So, take a look at this chart. I I want to get your take on it.Something I think is interesting is that this part right here, we haven't seen the MAG 7 hit a new high since all the way back in October. What are the charts telling us about the path forward. That's right.I think it's telling us that we're about to have that happen. This is what we call handle pattern. It's a bullish formation.What you do is have a breakout, you have a measure move, and ...

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided an update on the commercial launch of REZENOPY®. As ...

TEL AVIV, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today issued a letter to its shareholders from its Chief Executive Officer, Dan Teleman. Dear Shareholders, 2025 has been a transformational year for Nasus Pharma. We’ve made considerable progress building a strong, focused company with signific ...